Novo Nordisk, a prominent pharmaceutical company specializing in weight-loss and diabetes medications, has released its third-quarter financial results, which align with market expectations. The company reported that its operating profit for the quarter amounted to 33.8 billion Danish crowns (approximately $4.86 billion), reflecting a 26% increase compared to the same period last year. This figure...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
